Patents by Inventor Daniel L. Alkon

Daniel L. Alkon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230000943
    Abstract: A method for inducing synaptogenesis in a subject having a neurodegenerative disease, the method comprising administering an angiotensin or analogue thereof in a therapeutically effective amount to induce synaptogenesis in said subject. The neurodegenerative disease may be, for example, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, dementia, or mild cognitive impairment. The methods may also be generally directed to improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 5, 2023
    Applicant: Synaptogenix, Inc.
    Inventor: Daniel L. ALKON
  • Publication number: 20220357315
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Application
    Filed: July 26, 2022
    Publication date: November 10, 2022
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20220356161
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Application
    Filed: July 6, 2022
    Publication date: November 10, 2022
    Applicant: Synaptogenix, Inc.
    Inventors: Thomas J. NELSON, Daniel L. ALKON
  • Patent number: 11415574
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 16, 2022
    Assignee: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Patent number: 11390596
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 19, 2022
    Assignee: Synaptogenix, Inc.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Publication number: 20220184028
    Abstract: A method for treating or preventing amyotrophic lateral sclerosis (ALS) or other motor neuron disease in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to treat or prevent the motor neuron disease by activating PKC in the subject. The ALS may be, for example, classical ALS, primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). The PKC activating compound may be administered at an initial loading dose of about 15, 24, or 48 micrograms weekly in the first one week or consecutive two or three weeks, followed by doses of about 12, 20, or 40 micrograms alternately every two or three weeks for at least 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, or 30 total weeks.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 16, 2022
    Applicant: Synaptogenix, Inc.
    Inventor: Daniel L. ALKON
  • Publication number: 20220151973
    Abstract: The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 19, 2022
    Applicant: Synaptogenix, Inc.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Publication number: 20220133687
    Abstract: A method for treating or preventing a neurodegenerative disease in a subject, the method comprising administering an HGF activating compound in a therapeutically effective amount to treat or prevent the neurodegenerative disease by activating HGF in the subject. The neurodegenerative disease may be, for example, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, dementia, or mild cognitive impairment. The methods may also be more generally directed to improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 5, 2022
    Applicant: Synaptogenix, Inc.
    Inventor: Daniel L. ALKON
  • Publication number: 20220128577
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject. These methods comprise measuring the growth rate, size and/or protein amount of a subject's skin fibroblasts and/or lymphocytes, and determining whether these values differ in certain ways from those of corresponding non-Alzheimer's disease dementia cells. This invention also provides methods for determining whether an asymptomatic human subject is at risk from becoming afflicted with Alzheimer's disease.
    Type: Application
    Filed: February 26, 2020
    Publication date: April 28, 2022
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Patent number: 11273139
    Abstract: The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 15, 2022
    Assignee: Synaptogenix, Inc.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Patent number: 11173140
    Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 16, 2021
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventor: Daniel L. Alkon
  • Publication number: 20210308099
    Abstract: A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
    Type: Application
    Filed: June 18, 2021
    Publication date: October 7, 2021
    Applicant: Synaptogenix, Inc.
    Inventor: Daniel L. ALKON
  • Patent number: 11099174
    Abstract: The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: August 24, 2021
    Inventors: Florin V. Chirila, Tapan Kumar Khan, Daniel L. Alkon
  • Patent number: 11045447
    Abstract: A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
    Type: Grant
    Filed: June 28, 2020
    Date of Patent: June 29, 2021
    Assignee: Synaptogenix, Inc.
    Inventor: Daniel L. Alkon
  • Publication number: 20210132045
    Abstract: Methods of diagnosing Alzheimer's disease are provided. At least five methods of diagnostic measurements are presented: Method 1: Integrated score; Method 2: Average aggregate area per number of aggregates; Method 3: Cell migration analysis; Method 4: Fractal analysis; Method 5: Lacunarity Analysis. In certain embodiments, a sample of a subject's skin provides a network of fibroblasts that is imaged and a fractal dimension of the image is calculated. The fractal dimension can be compared to an aged-matched control (non-Alzheimer's) database to determine if the subject has Alzheimer's disease. The network of fibroblasts may be cultured in a matrix, for example in a protein mixture.
    Type: Application
    Filed: October 9, 2020
    Publication date: May 6, 2021
    Inventors: Florin Valentin CHIRILA, Tapan Kumar KHAN, Daniel L. ALKON
  • Publication number: 20210023048
    Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventor: Daniel L. ALKON
  • Patent number: 10821079
    Abstract: The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: November 3, 2020
    Assignee: Cognitive Research Enterprises, Inc.
    Inventors: Daniel L. Alkon, Thomas J. Nelson
  • Publication number: 20200331875
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 22, 2020
    Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. NELSON, Daniel L. ALKON
  • Publication number: 20200323817
    Abstract: A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
    Type: Application
    Filed: June 28, 2020
    Publication date: October 15, 2020
    Applicant: NEUROTROPE BIOSCIENCE, INC.
    Inventor: Daniel L. Alkon
  • Patent number: 10696644
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: June 30, 2020
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.
    Inventors: Thomas J. Nelson, Daniel L. Alkon